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ABSTRAK
Cakupan imunisasi dewasa yang rendah mungin berperan pada kejadian luar biasa (KLB) difteria baru-baru 
ini di Indonesia. Meskipun dikenal sebagai vaksin anak, vaksinasi difteria harus diberikan sebagai ulangan pada 
remaja dan dewasa untuk pencegahan jangka panjang. Vaksin dewasa berbeda dari vaksin anak tetapi memiliki 
proteksi yang sama. Selain itu, dianjurkan pula vaksinasi untuk ibu hamil dan orang lanjut usia di atas 65 tahun.
Kata kunci: difteria, vaksin, kehamilan, pediatrika, usia lanjut.
ABSTRACT
Low adult vaccination coverage in Indonesia may contribute to a recent outbreak of diphtheria in Indonesia. 
Although well known as a pediatric vaccine, diphtheria vaccination should be administered as booster to 
adolescence and adults for longer prevention. Adult vaccine differs from pediatric vaccine but have similar 
protection. Additionally, there is special recommendation to vaccinate pregnant women and elderly people 
aged 65 years or more.
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INTRODUCTION
Diphtheria is regarded as a reemerging 
disease since an outbreak occurs in the Soviet 
Union in 1990s, more than 2 decades after 
universal childhood immunization was initiated 
and controlled the disease.1 Recent outbreaks 
throughout the Indonesian archipelago last 
year reemphasizes the importance of childhood 
vaccination and adult boosters. During 2017, 
there were 954 cases of diphtheria with death 
toll reaching 44 (4.6%) cases.2 Consequently, an 
outbreak response immunization (ORI) program 
has been launched in mid-December 2017 to 
control the spread of the disease further.3
Unpublished data from the Ministry of 
Health, Republic of Indonesia showed that 
diphtheria cases did occur sporadically from1988 
to 2016 at the national level. Universal child 
immunization was launched in 1990 followed 
by vaccination for school-age children in 1999. 
Since 1990, diphtheria cases showed a fluctuation 
until an outbreak occurred in 2012. The outbreak 
was resolved in 2014, but it remained a potential 
problem due to a sociocultural resistance to 
vaccination among a small group of people.
DIPHTHERIA – THE DISEASE
Diphtheria is an acute bacterial disease 
caused by exotoxin-producing Corynebacterium 
diphtheria. Another toxin producing strain, i.e. 
C. ulcerans can cause a diphtheria-like illness.4 
It usually affects the tonsils, throat, nose and/or 
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skin. Respiratory diphtheria is the most common 
manifestation. It is characterized by a grayish-
colored pseudomembrane on the pharynx, 
palate, or nasal mucosa that can fatally obstruct 
the upper airway. The overall case-fatality for 
diphtheria is 5–10%.5 Cutaneous manifestation 
of diphtheria can occur, resulting in indolent skin 
infection. Transmission is by person-to-person 
contact through inhaling air droplets of infected 
person.
Symptoms of diphtheria may appear 2-4 
days after infection with an incubation period 
of 1-10 days. Most adult cases occur among 
unvaccinated or inadequately vaccinated people. 
Immunity after contracting diphtheria may not 
lifelong, so patients recovered from diphtheria 
are still need to be immunized. Diphtheria 
remains a public health problem in developing 
countries and potentially causes an outbreak.
Diphtheria antitoxin is predominated by 
immunoglobulin (IgG) induced after vaccination 
with diphtheria toxoid. Antitoxin concentrations 
of >0.1 IU/mL are generally considered 
protective, while concentration <0.01 IU/L are 
not protective.6 Periodic vaccination is required 
to maintain immunity. Immunity acquired from 
childhood vaccination wanes during adulthood 
if there are no decennial boosters. An American 
study showed that people with protective levels 
of diphtheria antibody decreased from 91% at 
6-11 years of age to only 29.5% at 70 years.7
VACCINE RECOMMENDATION
A tetanus-diphtheria-acellular pertussis 
(Tdap) vaccination gives protection against 
tetanus, diphtheria and pertussis. A tetanus-
diphtheria (Td) vaccination gives protection 
against both tetanus and diphtheria. The current 
recommendations are:8
• Tdap vaccine for adult >19 years: 1 dose if 
not vaccinated previously with Tdap;
• Td vaccine (booster) 1 dose every 10 years.
In addition, there is an off-label use of Tdap, 
i.e. for pregnant women, 1 dose each pregnancy 
preferably given at 27 – 36 weeks of gestation.
The Advisory Committee on Immunization 
Practices (ACIP) provides these recommendations 
in accordance to recommendations of the 
American Academy of Family Physicians 
(AAFP), the American College of Obstetricians 
and Gynecologists (ACOG), and the American 
College of Physicians (ACP).
AVAILABLE VACCINES
In general, there are 4 vaccines that include 
protection against diphtheria, i.e. DTaP, DT, 
Tdap and Td. The DTaP and DT are pediatric 
vaccines for infants and young children. Tdap 
is an inactive vaccine for adult primary vaccine, 
while Td is a booster vaccine. Compared with 
infant formulations DTaP and DT, Tdap and 
Td contains reduced quantities (10–50%) of 
all toxoids and antigens. The reduced antigen 
content is designed to avoid the increasing 
reactogenicity historically seen with the fourth 
and fifth doses of infant vaccine.
In the global market, there are 2 Tdap 
vaccines available, i.e. Adacel® (Sanofi Pasteur) 
for persons aged 11 – 64 years (16) and Boostrix® 
(GlaxoSmithKline) for persons aged 10 – 18 
years (17). Both vaccines are licensed for 
single-dose administration. They do not contain 
thimerosal or other preservative.
Each 0.5-mL dose of Adacel® contains 5 limit 
of flocculation (Lf) tetanus toxoid, 2 Lf diphtheria 
toxoid, and acellular pertussis antigens (2.5 µg 
detoxified PT, 5 µg FHA, 3 µg pertactin, 5 µg 
FIM). Each 0.5-mL dose of Boostrix® contains 5 
Lf of tetanus toxoid, 2.5 Lf of diphtheria toxoid, 8 
µg of inactivated PT, 8 µg of FHA, and 2.5 µg of 
pertactin (69 kiloDalton outer membrane protein).
Tetanus and diphtheria toxoids (Td) are also 
available for adults and adolescents in Indonesia, 
which is produced by Bio Farma Company as 
single dose (Bio Td) and multiple dose vials 
(Adsorbed Td Vaccine 10 doses). Each dose 
of 0.5 mL vaccine contains 7.5 Lf of tetanus 
toxoid and 2 Lf of diphtheria toxoid. Bio Farma 
is the only vaccine manufacturer in Indonesia 
recognized by World Health Organization and 
member of the Developing Countries Vaccine 
Manufacturers Network (DCVMN).9
Dose of Tdap or Td is 0.5 mL administered 
intramuscularly, preferably into the deltoid 
muscle.10 Simultaneous injections with other 
vaccine can be safely done at a different 
anatomical site.
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VA C C I N E  I M M U N O G E N I C I T Y  A N D 
EFFECTIVENESS
No controlled clinical trial of the efficacy 
of the toxoid in preventing diphtheria has ever 
been conducted. There is, however, strong 
evidence from observational studies to support 
the effectiveness of vaccination, although 
effectiveness of diphtheria toxoid does not reach 
100%:
Immunogenicity of the first dose Tdap 
vaccine given to adults is very good. The 
postvaccination antibody levels >0.1 IU/mL 
were achieved by 96.1% of participants. For 
those who have received Tdap vaccine 10 
years before, 98.5% participants achieved the 
protective antibody.11
Seroprotective diphtheria antibody levels 
were similar between TdaP and Td. The 
seroprotective concentration (> 0.1 IU/mL) can 
be achieved by 98% of adults receiving TdaP 
and Td vaccines.12
CONTRAINDICATIONS AND PRECAUTIONS
Tdap vaccine is contraindicated in:8
• Severe allergic reaction (e.g. anaphylaxis) 
after a previous dose or to a vaccine 
component.
• Encephalopathy (e.g. coma, decreased level 
of consciousness, or prolonged seizures) 
not attributable to another identifiable 
cause within 7 days of administration of 
previous dose of DTP, DTaP, Tdap. This 
is specifically a contraindication for the 
pertussis component of Tdap. If present, the 
person should receive Td instead of Tdap.
Td (and DT) is contraindicated in severe 
allergic reaction (e.g. anaphylaxis) after a 
previous dose or to a vaccine components.
When there is a history of anaphylactic 
reactions to the vaccine, the patient should be 
referred to an allergist to confirm the presence of 
specific allergy to tetanus toxoid and whether or 
not a desensitization therapy can be done.
In addition, there are several precautions of 
giving Tdap and Td vaccines, i.e.:8
• Progressive or unstable neurological disorder, 
uncontrolled seizures, or progressive 
encephalopathy until a treatment regimen 
has been established and the condition has 
stabilized; these precautions are for pertussis 
components (only for Tdap);
• Guillain-Barré syndrome <6 weeks after a 
previous dose of tetanus toxoid–containing 
vaccine; 
• History of Arthus-type hypersensitivity 
reactions after a previous dose of tetanus 
or diphtheria toxoid–containing vaccines; 
defer vaccination until at least 10 years 
have elapsed since the last tetanus toxoid–
containing vaccine; 
• Moderate or severe acute illness with or 
without fever. 
ADVERSE REACTIONS OF VACCINATION
Several adverse reactions have been reported 
after TdaP or Td vaccination. A study comparing 
TdaP and Td vaccines showed comparable 
post-vaccination symptoms. Among persons 
receiving TdaP and Td vaccines respectively, 
the reported local reactions are pain (30.7% and 
35.7%), swelling (4.2% and 2.5%), and erythema 
at the injection site (2.0% and 3.2%). The most 
frequent general symptoms were headache 
(20.4% and 15.7%), fatigue (17.0% and 14.5%), 
and myalgia (10.0% and 12.5%).12
Other studies have compared post-
vaccination adverse events between the naïve 
and repeat-dose groups. The reported adverse 
reactions were injection-site pain (84.4% and 
87.8%), erythema (29.7% and 23.1%), swelling 
(23.3% and 20.5%), and myalgia (53.5% and 
60.1%), headache (37.6% and 40.6%), malaise 
(29.0% and 29.4%), and fever (4.9% and 4.2%).11
VACCINATION DURING PREGNANCY 
The ACIP recommends pregnant women to 
receive Tdap vaccine between 27 and 36 weeks 
of gestation.8,13 This time period was consistently 
protective against acute respiratory infection 
(ARI) in the first 2 months of the infant’s life. A 
retrospective cohort study has included 99,434 
infants and compared the infants born from 
mothers vaccinated with Tdap during pregnancy 
and mothers who did not receive vaccination. 
The risk of ARI at <2 months of age was 9% less 
likely (relative risk [RR] = 0.91; 95% confidence 
interval [CI] = 0.84-0.99) in infants from mothers 
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who received Tdap vaccination. Furthermore, the 
risk was 17% lower if the mother was vaccinated 
between 27 and 36 weeks of pregnancy (RR = 
0.83; 95% CI = 0.74-0.93).14
VACCINATION FOR ELDERLY PEOPLE
Initially, Tdap vaccination or booster was 
recommended until the age of 64 years. Elderly 
people > 65 years of age was not recommended 
due to a lack of safety and immunogenicity data. 
However, lack of standalone pertussis vaccine 
has force the use of Tdap for people > 65 years 
due to prevent pertussis epidemic in this group 
of age.15 Immunizing older adults with Tdap not 
only reduce the risk of pertussis in the elderly but 
also prevent transmission to infants having close 
contact with them.
Study showed that in elderly people aged 
>65 years, Tdap and Td vaccine showed 
comparable safety. The most frequent adverse 
events were local injection-site reaction.16 There 
is no increased risk of reactogenicity after Tdap 
vaccination to people with a history of receiving 
Td vaccine within 5 years.17 Tdap vaccine can 
also be co-administered with influenza vaccine to 
subjects >65 years of age without compromising 
of either the reactogenicity or immunogenicity 
profiles of both vaccines.18
CONCLUSION
Diphtheria vaccination should be given 
to adults aged > 19 years with a decennial Td 
booster dose. A single dose of Tdap should be 
given to persons without a history of diphtheria 
vaccination. Continued protection against 
diphtheria (and tetanus) is provided by booster 
doses of Td every 10 years throughout life. 
Pregnant women should have Tdap vaccine 
in each pregnancy. Tdap vaccination is also 
recommended for elderly people >65 years of 
age. Tdap or Td vaccine is administered as a 
single dose of 0.5 mL, intramuscularly into the 
deltoid muscle.
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